Lung Cancer Treatment in China: Targeted Therapy, Immunotherapy, and Why Caseload Matters
China treats more than 700,000 new lung cancer cases each year. That scale brings deep institutional experience — and access to both globally approved drugs and innovative medicines developed and approved in China.
Quick Answer
Lung cancer is the most common cancer in China by both incidence and mortality, with more than 700,000 new cases diagnosed annually. Chinese oncologists carry substantial real-world experience across EGFR-targeted therapy, ALK inhibitors, and PD-1/PD-L1 immunotherapy — and have access to both internationally approved drugs and China-developed innovative medicines not yet available in all other countries. For international patients seeking treatment, a second opinion, or access to specific drugs, China offers a well-resourced lung cancer treatment environment supported by comprehensive molecular testing and multidisciplinary team (MDT) evaluation.
China records more than 700,000 new lung cancer diagnoses each year — one of the largest patient populations of any country — giving Chinese oncologists substantial real-world experience across the full treatment spectrum. For international patients seeking targeted therapy, immunotherapy, or a specialist second opinion, this translates into institutional depth in molecular testing, treatment sequencing, and access to both globally approved and China-based expert evaluation.
Why Patient Volume Translates Into Clinical Experience
Lung cancer is the leading cause of cancer-related death in China. Major oncology centers in Beijing, Shanghai, Guangzhou, and other cities treat thousands of lung cancer patients each year — in many cases, more than most oncology departments in smaller countries treat over several years. This volume has clinical consequences that matter for international patients:
- EGFR mutation management: Approximately 50% of NSCLC patients in East Asian populations carry EGFR mutations — far higher than in Western populations (~15%). Chinese oncologists have extensive experience sequencing first, second, and third-generation EGFR inhibitors and managing acquired resistance.
- Rare driver mutations: Even uncommon mutations — MET exon 14 skipping, RET fusion, NTRK fusion — generate meaningful caseloads at large centers, supporting specialist expertise.
- Complex treatment sequencing: Resistance to first-line targeted therapy, progression on immunotherapy, and second-line decisions are handled routinely in high-volume centers with MDT support.
- Access to clinical trials: High-enrollment centers in China participate in both domestic and international lung cancer trials, offering access to emerging treatment approaches.
For international patients who have already received treatment locally but are seeking a second opinion on whether a different drug sequence or mutation-targeted approach may be relevant, a structured MDT consultation with a Chinese lung cancer specialist team can provide an expert review of existing records without requiring immediate travel.
Molecular Testing: The Foundation of Targeted Lung Cancer Treatment
Before targeted therapy can be considered, comprehensive molecular profiling is required to identify which — if any — driver mutations are present. Major Chinese oncology centers typically offer next-generation sequencing (NGS) panels that can assess multiple targets simultaneously from tissue or plasma (liquid biopsy). The standard panel for NSCLC includes:
Actionable driver mutations tested
- •EGFR mutations (exon 19 del, exon 21 L858R, exon 20 ins, T790M, others)
- •ALK rearrangement
- •ROS1 fusion
- •KRAS G12C (and other KRAS variants)
- •MET exon 14 skipping and MET amplification
Additional targets assessed
- •RET fusion
- •NTRK fusion
- •HER2 (ERBB2) mutation — particularly exon 20 insertion
- •BRAF V600E
- •PD-L1 expression (TPS/CPS, for immunotherapy eligibility)
For international patients: If molecular testing has already been performed locally, bringing full NGS reports — not just summary results — is important. Chinese specialists may identify actionable findings that were not pursued, or may recommend re-biopsy if prior testing was limited in scope. Liquid biopsy (plasma ctDNA) can also be arranged at Chinese centers if tissue is unavailable or insufficient.
EGFR-Targeted Therapy in China — Including China-Developed Third-Generation Inhibitors
For patients with EGFR-mutated NSCLC, targeted therapy is the standard first-line approach. China is notable for having developed and approved its own third-generation EGFR tyrosine kinase inhibitors (TKIs) — drugs that address the T790M resistance mutation and deliver CNS penetration — in addition to the internationally developed options.
Third-Generation EGFR Inhibitors
Third-generation EGFR TKIs are now standard of care for EGFR-mutated NSCLC in most settings. China has access to both the internationally developed osimertinib and two NMPA-approved drugs developed by Chinese pharmaceutical companies:
Osimertinib (奥希替尼 / Tagrisso)
AstraZeneca. Globally approved. Available in China. Standard first-line option for classical EGFR mutations (exon 19 del, L858R).
Aumolertinib (阿美替尼 / 艾弗沙)
Hansoh Pharma. NMPA approved. China-developed third-generation EGFR TKI with published Phase III data demonstrating clinical activity in EGFR-mutated NSCLC. Not yet available in most Western markets.
Furmonertinib (伏美替尼)
Allist Pharmaceuticals. NMPA approved. Another China-developed third-generation EGFR TKI with published efficacy and safety data for EGFR-mutated NSCLC including T790M resistance mutation.
Drug selection depends on individual mutation profile, prior treatment history, CNS involvement, performance status, and other clinical factors. A specialist evaluation is required.
First and Second-Generation EGFR Inhibitors
First-generation drugs (gefitinib 吉非替尼, erlotinib 厄洛替尼) and second-generation drugs (afatinib 阿法替尼 — which also covers HER2) remain available and may be used in specific clinical contexts, particularly where third-generation agents are contraindicated or in patients with certain atypical EGFR mutations. Treatment selection is determined by the treating oncologist based on individual case assessment.
ALK, MET, RET, KRAS, and Other Driver Mutation Therapies
Beyond EGFR, China has access to targeted agents for a range of other actionable driver mutations — including several drugs developed or co-developed in China with clinical data generated primarily in Chinese patient populations.
ALK Rearrangement (~5–8% of NSCLC)
MET Exon 14 Skipping and MET Amplification (~3–4% of NSCLC)
Other Actionable Targets
Eligibility for any targeted therapy requires confirmation of the relevant driver mutation through validated molecular testing. Drug selection, dosing, and sequencing are determined by the treating oncology team based on individual clinical and pathological factors.
Seeking a second opinion on lung cancer drug options?
If you have already received molecular testing results but are uncertain whether all actionable findings have been addressed, a structured expert review of your records may help clarify whether additional targeted therapy or immunotherapy options should be considered.
Request a Case ReviewImmunotherapy for Lung Cancer in China — Including China-Developed PD-1 Inhibitors
For patients whose tumours do not carry a targetable driver mutation — or whose tumours have progressed after targeted therapy — immunotherapy using PD-1 or PD-L1 checkpoint inhibitors is a central treatment approach. China has both internationally developed PD-1/PD-L1 drugs and a growing number of domestically developed checkpoint inhibitors that have received NMPA approval for lung cancer indications.
Internationally Developed PD-1 / PD-L1 Inhibitors Available in China
Pembrolizumab (帕博利珠单抗 / Keytruda)
Merck
Standard of care for high PD-L1 NSCLC; approved in combination with chemotherapy
Nivolumab (纳武利尤单抗 / Opdivo)
Bristol-Myers Squibb
Available in China for NSCLC and other tumor types
Atezolizumab (阿替利珠单抗 / Tecentriq)
Roche/Genentech
PD-L1 inhibitor; used in NSCLC and SCLC combinations
Durvalumab (度伐利尤单抗 / Imfinzi)
AstraZeneca
Standard of care after chemoradiation for unresectable stage III NSCLC
China-Developed PD-1 Inhibitors — NMPA Approved for Lung Cancer
Chinese pharmaceutical companies have developed several PD-1 inhibitors that have received NMPA approval for specific lung cancer indications, with Phase III clinical trial data generated largely in Chinese patient populations. These drugs typically offer cost advantages compared with internationally developed counterparts.
Sintilimab (信迪利单抗 / 达伯舒)
Innovent Biologics
NMPA approved in combination with chemotherapy for NSCLC. Extensive published clinical data in Chinese patients.
Camrelizumab (卡瑞利珠单抗 / 艾瑞卡)
Hengrui Medicine
NMPA approved for NSCLC in combination regimens. One of the most widely used PD-1 inhibitors in China.
Tislelizumab (替雷利珠单抗 / 百泽安)
BeiGene
NMPA approved for multiple indications including NSCLC. Also approved in some international markets.
Sugemalimab (舒格利单抗 / 择捷美)
CStone Pharmaceuticals
NMPA approved specifically for NSCLC — including stage III after chemoradiation and metastatic NSCLC in combination with chemotherapy. Phase III data generated in Chinese NSCLC patients.
PD-L1 expression level, tumor mutational burden (TMB), histology, and performance status all influence immunotherapy eligibility and drug selection. All decisions are made by the treating oncology team.
Combination approaches: For most NSCLC patients without a targetable driver mutation, chemo-immunotherapy combinations — rather than immunotherapy alone — are the standard first-line approach. Chinese centers routinely use both internationally developed and domestically developed PD-1/PD-L1 inhibitors in these combination regimens, often with published real-world outcome data specific to Chinese patient cohorts.
MDT Evaluation and Second Opinion for Lung Cancer in China
At major Chinese oncology centers, lung cancer cases are routinely reviewed through multidisciplinary team (MDT) meetings involving oncologists, pulmonologists, thoracic surgeons, radiologists, pathologists, and radiation oncologists. For international patients, this structure also supports remote case review — expert evaluation of existing records before any decision about travel.
When a Chinese MDT second opinion may be relevant
- Molecular testing has identified a driver mutation that local oncologists are less familiar with (e.g., rare EGFR mutations, MET, RET, NTRK)
- A China-developed drug (aumolertinib, furmonertinib, savolitinib) may be relevant but is not available locally
- Disease has progressed after first-line targeted therapy and treatment sequencing options are uncertain
- Immunotherapy eligibility is unclear or conflicting opinions have been received
- A clinical trial at a Chinese center may be relevant to the specific mutation profile
- The patient is of East Asian heritage and wants evaluation by specialists with highest volume in this population
A structured remote review requires pathology reports, full molecular testing results (including raw NGS data where available), imaging reports, and treatment history. ChinaMed Waypoint helps organise records and facilitate communication as part of the cancer treatment coordination pathway.
Supportive Care During Lung Cancer Treatment in China
Lung cancer treatment — whether targeted therapy, immunotherapy, or chemotherapy — can involve significant side effects and fatigue. In China, integrative supportive approaches may be offered alongside standard oncology treatment. These include nutritional support, fatigue management, and in some settings Traditional Chinese Medicine (TCM) approaches used as complementary support during or between treatment cycles.
Important: Supportive and integrative care in China is used alongside — not instead of — standard oncology treatment. TCM or other integrative approaches would be coordinated by the treating team and would not replace targeted therapy, immunotherapy, chemotherapy, or radiotherapy.
More on supportive and integrative care approaches during cancer treatment is available in our Traditional Chinese Medicine and supportive care resources.
Related Guides
How Targeted Cancer Drugs Work
A plain-language guide to targeted therapy — how drugs like EGFR inhibitors identify and block specific cancer-driving molecular changes.
Immunotherapy After Treatment Failure
Options when lung cancer or other cancers progress after standard treatment — including PD-1 inhibitors and combination approaches.
Cancer Options When Standard Treatment Fails
A structured guide to evaluating next steps — clinical trials, second opinion, alternative drug access — when first-line treatment is no longer working.
Frequently Asked Questions
Why do Chinese patients have higher EGFR mutation rates in lung cancer?
EGFR mutations are found in approximately 50% of NSCLC patients in East Asian populations, compared with roughly 15% in Western populations. The reasons are not fully understood but likely reflect a combination of genetic background and histological differences in lung cancer subtype. This higher rate means Chinese oncologists have accumulated exceptional clinical experience with EGFR-targeted therapy, including managing resistance and sequencing multiple generations of EGFR inhibitors.
What targeted therapy drugs for lung cancer are available in China that may not be accessible elsewhere?
China-developed drugs with NMPA approval that are not yet available in all other countries include aumolertinib (艾弗沙) and furmonertinib (伏美替尼) — both third-generation EGFR inhibitors — and savolitinib (赛沃替尼), a selective MET inhibitor for MET exon 14 skipping NSCLC. Access and eligibility depend on individual mutation profile, prior treatment history, and clinical assessment.
What immunotherapy options exist for lung cancer in China?
Both globally developed PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab) and China-developed PD-1 inhibitors with NMPA approval (sintilimab, camrelizumab, tislelizumab, sugemalimab) are available. Immunotherapy is typically used in combination with chemotherapy for patients without a targetable driver mutation. Eligibility depends on PD-L1 expression, mutation profile, and performance status.
What molecular tests should be done before starting lung cancer treatment?
For NSCLC, a comprehensive molecular panel should include EGFR, ALK, ROS1, KRAS G12C, MET exon 14 skipping and amplification, RET, NTRK, HER2, and PD-L1 expression. Next-generation sequencing (NGS) panels are standard at major Chinese centers and can assess multiple targets simultaneously from tissue or plasma. If prior testing was limited, a Chinese specialist may recommend extended molecular profiling before treatment decisions are made.
How can international patients access lung cancer evaluation in China?
International patients can request a remote structured case review — including expert evaluation of existing pathology, molecular testing results, imaging, and treatment history — without an initial travel commitment. ChinaMed Waypoint helps organise records, facilitate bilingual communication with Chinese oncology teams, and support coordination through the evaluation and, if appropriate, treatment process. All clinical decisions are made by the treating specialist team.
Medical Disclaimer: ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. Drug names, indications, and availability described in this article reflect general information about the lung cancer treatment landscape in China and may change as regulatory approvals evolve. Individual eligibility for any treatment depends on diagnosis, molecular profile, prior treatment history, and clinical assessment by a qualified oncologist. All treatment decisions should be made in consultation with a qualified oncologist or relevant specialist.
Request a Lung Cancer Case Review With a Chinese Specialist Team
Whether you are exploring targeted therapy options, immunotherapy eligibility, or want a second opinion on your current treatment plan, a structured expert review of your records is the appropriate first step — before any travel decision.